PSA Screening for HIM Act
- Sponsor
- Rep. Dunn, Neal P. [R-FL-2]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Feb 13, 2025
Bottom line
The bill aims to increase early detection of prostate cancer in high-risk men by eliminating out-of-pocket screening costs, while also reinforcing broader breast cancer screening coverage.
What it actually does
This bill amends the Public Health Service Act to mandate that group health plans and health insurance issuers provide coverage for prostate cancer screenings without cost-sharing for men aged 40 and over who are at high risk of developing the disease. High-risk is defined to include African-American men and men with a family history of prostate cancer. Additionally, it clarifies that breast cancer screening recommendations should exclude those issued by the USPSTF in or around November 2009.
Proponents argue
Supporters emphasize that prostate cancer is a leading cause of cancer death in men, with significantly higher rates and mortality among African-American men. They argue that early detection dramatically improves survival rates, and removing cost barriers for high-risk individuals will lead to earlier diagnoses, better health outcomes, and potentially reduce the much higher costs associated with treating late-stage metastatic cancer.
Opponents contend
Potential opponents might raise concerns about the overall cost implications for health insurance plans and the healthcare system, arguing that mandating specific screenings could lead to increased premiums. While the bill targets high-risk men, some critics might still point to the broader debate around PSA screening, including the potential for overdiagnosis and overtreatment of slow-growing cancers, even if these concerns are somewhat mitigated by the bill's targeted approach.
The bill is exceptionally concise and clearly written, allowing for a quick and thorough understanding of its provisions, making it highly accessible to any interested reader.
Section 3(a) amending 42 U.S.C. 300gg-13(a)(1)(E)
Mandatory Coverage for Prostate Cancer Screenings for High-Risk Men
This provision requires group health plans and health insurance issuers to cover prostate cancer screenings for men aged 40 and over who are at high risk, without imposing any cost-sharing requirements. High-risk men are explicitly defined as African-American men and men with a family history of prostate cancer. This expands the list of preventive services that must be covered at no cost to the patient, aiming to remove financial barriers to early detection.
Supporters argue
Supporters argue this provision directly addresses significant health disparities and improves health outcomes by removing financial barriers for those most vulnerable to prostate cancer. They highlight the high survival rate of early-stage cancer and the lack of symptoms in early stages, making screening crucial for high-risk populations.
Critics contend
Critics might argue that mandating specific screenings, even for high-risk groups, could lead to increased healthcare costs for insurers, which may be passed on to consumers through higher premiums. There are also ongoing debates about the efficacy and potential harms (e.g., false positives, overtreatment) of PSA screening, even for high-risk groups, though the bill's focus on high-risk men aims to mitigate some of these general concerns.
Tradeoffs
The bill balances the benefit of early detection and improved outcomes for high-risk men against the potential for increased healthcare costs for insurers and the ongoing medical debate about the overall utility and potential harms of PSA screening, even when targeted.
Section 3(a) amending 42 U.S.C. 300gg-13(a)(2)
Definition of 'Men with a family history of prostate cancer'
This section provides a precise definition for 'men with a family history of prostate cancer' to clarify eligibility for the mandated no-cost screenings. It includes men who have a first-degree relative (parent, sibling, child) who was diagnosed with, developed, or died from prostate cancer, or who has a cancer or genetic alteration known to increase prostate cancer risk.
This provision clarifies that for the purposes of breast cancer screening, mammography, and prevention, the 'current recommendations of the United States Preventive Service Task Force' shall be considered those other than the ones issued in or around November 2009.
Section 3(a) amending 42 U.S.C. 300gg-13(a)(3)
Why it matters:This could be a strategic legislative maneuver to include a provision with potentially broader political implications within a bill that has strong support for its main purpose, or it could simply be a legislative vehicle for related health policy adjustments.
Case for: Supporters argue this clarification ensures that women continue to receive comprehensive breast cancer screening coverage, preventing a rollback of benefits based on potentially controversial or outdated guidelines from a specific period, thereby protecting access to vital preventive care.
Case against: Critics of overriding USPSTF recommendations generally argue that it undermines evidence-based medicine and could lead to unnecessary screenings or increased costs if not aligned with the most current scientific consensus, potentially diverting resources from more effective interventions.
Estimated impact: Ensures continued or broader coverage for breast cancer screenings for millions of women, potentially impacting insurance costs and public health outcomes related to breast cancer detection by maintaining access to screenings that might otherwise be restricted.